A Single-arm, Phase II Clinical Trial to Treat Muscle-invasive Bladder Cancer With Neoadjuvant Chemotherapy Plus Anti-PD-1 Therapy Followed by Radiotherapy Plus Concurrent Anti-PD-1 Therapy
| Registry | NCT05975307, acronym BCIRT-01 |
|---|---|
| Status | Active not recruiting |
| Phase | Phase 2 |
| Study type | Interventional; na, single group, masking: none, treatment |
| Enrollment | 71 (Estimated) |
| Sponsor | Sun Yat-sen University (Other) |
| Conditions | Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy |
| Interventions | Toripalimab, Gemcitabine, Cisplatin, Carboplatin, Intensity-modulated radiation therapy (Drug, radiation) |
| Dates | start 2023-12-01, primary completion 2025-12-31 (estimated), completion 2029-12-31 (estimated), first posted 2023-08-03, last updated 2025-12-01 |
| Locations | 1 site in China |
Related Papers Related Patents Related Grants Related Experts
All trials for Muscle-Invasive Bladder Carcinoma All trials for Programmed Cell Death Protein 1 Inhibitor All trials of Toripalimab All trials of Gemcitabine
The goal of this Phase 2 trial is to evaluate a non-surgical bladder-preserving treatment mode which consists of neoadjuvant chemotherapy plus anti-programmed cell death protein 1 (anti-PD-1) therapy followed by radiotherapy plus concurrent anti-PD-1 therapy. The main questions it aims to answer are: (i) whether the anti-PD-1 antibody, toripalimab, is effective in treating muscle-invasive bladder cancer (MIBC), when combined with chemoradiation; (ii) whether toripalimab is safe in combination with chemoradiation. Participants will receive 3 cycles of neoadjuvant treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy plus 2 cycles of concurrent toripalimab.
Bladder cancer is the second most common malignancies over the world. At initial diagnosis, the cases with muscle-invasive bladder cancer (MIBC) accounts nearly 20% of all bladder cancer patients. And 40% of non-muscle-invasive bladder cancer could develop to MIBC. Currently, radical cystectomy (RC) is the golden standard to manage MIBC. Yet, it brings severe surgical injuries and post-surgical complications which impair life quality of the patients. Recently, bladder-preserving treatment based gradually becomes the second choice for MIBC. It consists of maximal transurethral resection of bladder tumor (TURBT) and chemoradiation. A series of clinical trials and meta-analyses supported that the bladder-preserving treatment has a similar therapeutic effect compared with RC. But it is noteworthy that this treatment mode does not really avoid surgery. TURBT could also cause complications, such as haemorrhage, infection, perforation, and even tumor dissemination. Moreover, the incidence of serious toxicities brought by concurrent chemoradiation is as high as 36%. In actual clinical work, it is hard for more than half patients to complete chemoradiation of standard intensity. Additionally, many patients are unsuitable for bladder preservation, including those with T stage > T2, diameter > 5 cm, hydronephrosis and positive lymph nodes. Hence, it calls for improvement of current bladder preservation mode, to make more MIBC patients receive radical treatment which brings better therapeutic experience and life quality.
Many lab studies indicated that formation and progression of bladder cancer is a process of mutation accumulation. It provides biological fundamentals for immune checkpoint inhibitors, such as anti-programmed cell death protein 1 (anti-PD-1) antibodies. Based on available clinical studies, anti-PD-1 antibodies exhibits ideal therapeutic effects in bladder cancer of different stages and has an incidence of toxicities as low as 13%. Its toxicities mainly include arthralgia and hyponatremia, which are well tolerated. Currently, there are more than 10 clinical trials trying anti-PD-1 antibodies for bladder preservation. However, the treatment modes in most of them still contain TURBT. This phase 2 trial intended to evaluate the therapeutic and adverse effects of a non-surgical bladder-preserving treatment mode consisting of anti-PD-1 antibodies and chemoradiation, in a small patient cohort with MIBC. The results might provide an effective, non-invasive and low-toxic choice which improves patient experience and realizes bladder preservation.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Toripalimab plus chemoradiation | Experimental | Drug: Toripalimab; Drug: Gemcitabine; Drug: Cisplatin; Drug: Carboplatin; Radiation: Intensity-modulated radiation therapy | This study has only single arm in which the patients will receive neoadjuvant chemotherapy plus anti-PD-1 therapy (toripalimab), followed by radiotherapy plus concurrent anti-PD-1 therapy |
Sex: All, ages: 18 Years to 75 Years
Inclusion Criteria: * Pathologically diagnosed bladder malignant tumor via biopsy * Urothelial carcinoma as the primary histological component * Pretreatment clinical TNM stage as T2-4aN0M0 or T1-4aN1-2M0 (UICC TNM staging classification, version 8) * Age between 18 and 75 years old * Karnofsky performance score ≥ 70 * Creatinine clearance rate ≥ 30 ml/min Exclusion Criteria: * Simultaneous tumors of the urethra or upper urinary tract * Existence of small cell cancer component * Uncontrolled tuberculosis, viral hepatitis or AIDS * Autoimmune or mental diseases * Severe cardiac, renal, hepatic or hematopoietic dysfunctions unsuitable for chemotherapy, radiotherapy or immune checkpoint inhibiting therapy * Prior history of other malignancies within 5 years, except cured cervical carcinoma in situ and skin basal cell carcinoma * Prior history of pelvic radiotherapy or chemotherapy * Poor adherence to regular follow-up (cystoscopy, CT, MRI, etc.) * Pregnant or lactating women * Treatment with glucocorticoid or immunosuppressive drugs within 1 month * Other situations for which the investigators consider a patient inappropriate to participate
| Facility | City | Country | Status |
|---|---|---|---|
| Cancer Center, Sun Yat-sen University | Guangzhou, Guangdong | China |